uniQure (NASDAQ:QURE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of uniQure (NASDAQ:QURE - Get Free Report) have earned an average rating of "Moderate Buy" from the eleven ratings firms that are currently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $37.82.

A number of equities research analysts have commented on the company. HC Wainwright restated a "buy" rating and set a $70.00 price objective on shares of uniQure in a research report on Thursday, May 29th. Wall Street Zen upgraded uniQure from a "sell" rating to a "hold" rating in a research report on Saturday, May 24th. Guggenheim restated a "buy" rating and set a $28.00 price objective on shares of uniQure in a research report on Monday, May 12th. Chardan Capital restated a "buy" rating and set a $38.00 price objective on shares of uniQure in a research report on Friday, May 30th. Finally, Wells Fargo & Company decreased their price objective on uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a research report on Friday, February 28th.

Institutional Investors Weigh In On uniQure

Institutional investors have recently made changes to their positions in the company. Palumbo Wealth Management LLC acquired a new stake in uniQure in the 4th quarter worth approximately $437,000. Oppenheimer & Co. Inc. acquired a new stake in uniQure in the 4th quarter worth approximately $320,000. Raymond James Financial Inc. acquired a new stake in uniQure in the 4th quarter worth approximately $1,951,000. Monaco Asset Management SAM acquired a new stake in uniQure in the 4th quarter worth approximately $2,414,000. Finally, Twin Tree Management LP acquired a new stake in uniQure in the 4th quarter worth approximately $77,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Trading Down 0.7%

QURE traded down $0.12 during trading on Friday, reaching $16.22. The company had a trading volume of 1,134,284 shares, compared to its average volume of 1,920,009. The firm's 50-day simple moving average is $13.16 and its 200 day simple moving average is $13.39. The company has a market cap of $888.47 million, a price-to-earnings ratio of -3.27 and a beta of 0.08. uniQure has a 12-month low of $3.73 and a 12-month high of $19.18. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, topping analysts' consensus estimates of ($1.07) by $0.25. The firm had revenue of $1.57 million for the quarter, compared to analysts' expectations of $5.93 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. Equities research analysts anticipate that uniQure will post -3.75 earnings per share for the current year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.